Handa Pharmaceuticals, Inc. (TPEX:6620)
Taiwan · Delayed Price · Currency is TWD 82.20
-0.10 (-0.12%)
Sep 5, 2025, 2:59 PM CST
Handa Pharmaceuticals Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 620.7 | 472.74 | 726.89 | -40.01 | -247.67 | -282.1 | Upgrade |
Depreciation & Amortization | 88.83 | 10.16 | 12.15 | 14.82 | 16.49 | 16.59 | Upgrade |
Other Amortization | 0.27 | 0.27 | 0.3 | 0.36 | 18.67 | 39.4 | Upgrade |
Loss (Gain) From Sale of Assets | 0.19 | 0.19 | -4.61 | 0 | -0.02 | 0 | Upgrade |
Asset Writedown & Restructuring Costs | - | - | - | - | - | 4.5 | Upgrade |
Loss (Gain) on Equity Investments | 4.62 | 1.81 | -2.37 | - | - | - | Upgrade |
Stock-Based Compensation | 15.97 | 22.39 | 8.47 | 0.11 | 0.26 | 0.64 | Upgrade |
Other Operating Activities | -46.99 | -189.23 | 51.87 | -5.55 | -13.62 | -38.04 | Upgrade |
Change in Accounts Receivable | -463.14 | 207.08 | -226.18 | -140.58 | 13.41 | -2.25 | Upgrade |
Change in Inventory | 40.08 | - | - | 10.11 | - | - | Upgrade |
Change in Accounts Payable | 14.47 | 6.57 | 8.34 | 5.1 | -8.26 | -4.66 | Upgrade |
Change in Other Net Operating Assets | -22.73 | -34.38 | 93.51 | -55.93 | 41.51 | -42.55 | Upgrade |
Operating Cash Flow | 252.27 | 497.6 | 668.36 | -211.57 | -179.24 | -308.47 | Upgrade |
Operating Cash Flow Growth | -66.21% | -25.55% | - | - | - | - | Upgrade |
Capital Expenditures | -15.61 | -7.77 | -0.94 | -0.64 | -5.58 | -7.41 | Upgrade |
Sale of Property, Plant & Equipment | 0 | 0 | - | 0 | 0.03 | - | Upgrade |
Cash Acquisitions | -978.92 | -819.63 | - | - | - | - | Upgrade |
Divestitures | - | - | -10.97 | - | - | - | Upgrade |
Sale (Purchase) of Intangibles | -0.17 | - | - | -0.12 | -1.57 | - | Upgrade |
Investment in Securities | -166.25 | 431.12 | -1,653 | 30.71 | 3.98 | 189.21 | Upgrade |
Other Investing Activities | 0.12 | -0.65 | - | -0.45 | 0.23 | -0.08 | Upgrade |
Investing Cash Flow | -1,161 | -396.92 | -1,665 | 29.5 | -2.91 | 181.72 | Upgrade |
Short-Term Debt Issued | - | - | - | - | - | 4.6 | Upgrade |
Total Debt Issued | - | - | - | - | - | 4.6 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | - | -4.6 | Upgrade |
Long-Term Debt Repaid | - | -6.07 | -7.17 | -7.19 | -7.77 | -8.1 | Upgrade |
Total Debt Repaid | -6.66 | -6.07 | -7.17 | -7.19 | -7.77 | -12.7 | Upgrade |
Net Debt Issued (Repaid) | -6.66 | -6.07 | -7.17 | -7.19 | -7.77 | -8.1 | Upgrade |
Issuance of Common Stock | 1,158 | 3.12 | 1,313 | 320.83 | 170.68 | 2.74 | Upgrade |
Repurchase of Common Stock | -114.4 | -56.52 | - | - | - | - | Upgrade |
Common Dividends Paid | - | -141.09 | - | - | - | - | Upgrade |
Financing Cash Flow | 1,037 | -200.55 | 1,306 | 313.65 | 162.91 | -5.36 | Upgrade |
Foreign Exchange Rate Adjustments | 32.23 | 30.2 | -8.34 | -28.97 | 2.44 | 1.75 | Upgrade |
Net Cash Flow | 160.2 | -69.67 | 301.13 | 102.6 | -16.81 | -130.37 | Upgrade |
Free Cash Flow | 236.66 | 489.84 | 667.42 | -212.21 | -184.82 | -315.88 | Upgrade |
Free Cash Flow Growth | -68.23% | -26.61% | - | - | - | - | Upgrade |
Free Cash Flow Margin | 17.69% | 58.97% | 60.33% | -107.35% | -632.19% | -1094.57% | Upgrade |
Free Cash Flow Per Share | 1.61 | 3.47 | 4.95 | -1.69 | -1.57 | -2.73 | Upgrade |
Cash Interest Paid | 0.49 | 0.49 | 0.22 | 0.28 | 0.23 | 0.45 | Upgrade |
Cash Income Tax Paid | 197.46 | 197.46 | 7.78 | 2.42 | 0.45 | -0.03 | Upgrade |
Levered Free Cash Flow | 498.95 | 438.42 | 450.86 | -224.91 | -74.36 | -175.3 | Upgrade |
Unlevered Free Cash Flow | 499.47 | 438.73 | 450.99 | -224.74 | -74.21 | -175.02 | Upgrade |
Change in Working Capital | -431.33 | 179.27 | -124.33 | -181.31 | 46.66 | -49.46 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.